Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) has partnered with USA Swimming to provide COVID-19 testing using the BD Veritor™ Plus System at various swimming events, including the U.S. Olympic Team Trials in June 2021. This initiative includes over 2,000 rapid antigen tests, supplementing existing PCR testing protocols to enhance athlete safety. BD's rapid testing technology delivers results in 15 minutes, promoting health and safety for competitors. This collaboration underscores BD's commitment to supporting athletes and ensuring safe participation in sports amidst the pandemic.
BD (Becton, Dickinson and Company) has secured pandemic orders for 2 billion injection devices to aid global COVID-19 vaccination efforts. This milestone includes commitments from over 40 countries and various NGOs. To date, BD has delivered over 900 million devices, with the remaining orders scheduled for delivery by the end of 2022. Additionally, BD plans to expand its manufacturing capacity with a $70 million project in Nebraska and invest $1.2 billion in upgrading facilities. The company was recognized at the 2021 World Vaccine Congress for its role in vaccination support.
BD (Becton, Dickinson and Company) has been named the first medical technology company to serve as a Common Vulnerability and Exposures (CVE) Numbering Authority. This designation allows BD to assign CVE ID numbers to new vulnerabilities in its software-enabled products, thus enhancing global cybersecurity efforts. The initiative aims to improve vulnerability management and assist customers in addressing cybersecurity risks. BD's established Coordinated Vulnerability Disclosure program and Cybersecurity Trust Center reflect its commitment to transparency and cybersecurity in medical devices.
BD (Becton, Dickinson and Company) announces its participation in two key virtual investor conferences in June 2021. The Piper Sandler June Med Tech Series Conference will take place on June 4 at 1:30 p.m. ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 8:50 a.m. ET. Live webcasts of the presentations and related materials can be accessed via BD's investor website, with replays available for a minimum of seven days following each event.
BD (Becton, Dickinson and Company) has launched a new Urine Culture Application in the U.S. for the BD Kiestra™ lab automation system. This innovative application employs artificial intelligence and digital imaging to enhance urine culture analysis by efficiently categorizing samples based on growth significance. By automating the sorting process, it allows laboratories to prioritize critical specimens, thus increasing operational efficiency. The application is expected to support microbiology labs in managing their workloads, especially amid a skilled technician shortage exacerbated by the COVID-19 pandemic.
BD (Becton, Dickinson and Company) has launched the BD Surgiphor™ Sterile Wound Irrigation System, marking a significant advancement as the first ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution. This product is designed to mechanically clean surgical wounds while providing a 99.99% reduction in bacteria. The system aims to simplify wound irrigation procedures for hospitals, adhering to safety standards set by U.S. health agencies. Acquired from Orthophor in November 2020, this product enhances BD's surgical portfolio, potentially increasing their market presence in the surgical domain.
BD (Becton, Dickinson and Company) will invest €165 million ($200 million USD) to establish a high-tech manufacturing facility in Zaragoza, Spain, projected to create 600 jobs by 2030. The construction is set to start in late 2021, contributing to BD's 2025 growth strategy of expanding pre-filled syringe manufacturing capacity. The new plant will be fully digital, aligning with sustainability standards, and aims to support COVID-19 vaccination efforts and other biologic drug deliveries in the European market.
BD (Becton, Dickinson and Company) announced a significant milestone with the CE marking of the industry's first self-collection HPV screening assay. This advancement allows laboratories to process samples collected by patients themselves using BD's Onclarity™ HPV Assay, enhancing accessibility for women hesitant to undergo clinical screening. Approximately 61,000 women are diagnosed with cervical cancer in Europe annually, highlighting an urgent need for improved screening strategies, especially post-COVID-19. The assay detects 14 high-risk HPV types, contributing to more effective cervical cancer prevention efforts.
BD (Becton, Dickinson and Company) reported Q2 fiscal 2021 revenues of $4.9 billion, a 15.4% year-over-year increase, driven by $480 million in COVID-19 diagnostic sales. Diluted EPS rose 77.4% to $0.94, with adjusted EPS of $3.19 reflecting a 25.1% increase. The company maintains an outlook for 12%-14% revenue growth and $12.75-$12.85 adjusted EPS for the full year. Key milestones include the 510(k) submission for the BD Alaris™ System and a planned spin-off of its diabetes business.
BD has announced a plan to spin off its Diabetes Care business into an independent company, referred to as NewCo. This strategic move is aimed at enhancing growth and allowing both entities to focus better on their core markets. In fiscal 2020, the Diabetes Care business generated nearly $1.1 billion in revenue. The spinoff is expected to be tax-free for U.S. federal income tax purposes and is anticipated to be completed in the first half of 2022, subject to approvals. This decision reflects BD's commitment to its 2025 strategy aimed at maximizing value for stakeholders.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
